<DOC>
	<DOCNO>NCT01755845</DOCNO>
	<brief_summary>The purpose study determine efficacy safety consolidation chemotherapy paclitaxel plus cisplatin ( 2 cycle per 3 week ) follow radical hysterectomy adjuvant chemoradiation ( 2 cycle per 4 week ) high risk early stage cervical cancer .</brief_summary>
	<brief_title>Trial Postoperative Chemoradiotherapy With Without Consolidation Chemotherapy Cervical Cancer Patients</brief_title>
	<detailed_description>Cervical carcinoma one common gynecologic cancer worldwide . Early stage cervical cancer treat effectively either radiotherapy radical hysterectomy plus pelvic lymph node dissection . However , several pathological risk factor , lymph node metastasis , involvement vaginal resection margin , parametrial invasion , identify compromise patient prognosis . Concurrent radiotherapy cisplatin-based chemotherapy become standard treatment patient cervical cancer . However , many patient pathological risk factor treat concurrent radiotherapy plus single agent cisplatin still suffer local distant relapse . How improve treatment outcome patient important issue require clinical investigation . Paclitaxel demonstrate good radiosensitizer . In addition , paclitaxel/cisplatin combination chemotherapy demonstrate superior progression-free survival platinum alone phase Ⅱ study . In addition , yet know whether chemotherapy radiation therapy effective give consolidation chemotherapy treat cervical cancer . Therefore , investigator go perform efficacy safety study postoperative concurrent paclitaxel/cisplatin chemotherapy radiotherapy consolidation chemotherapy high-risk patient early-stage cervical cancer follow radical hysterectomy .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Undertaken radical hysterectomy diagnosis invasive cervical cancer I a2II b ( nonsmall cell type ) One risk factor ( lymph node involvement , resection margin involvement , parametrial involvement ) Eastern Cooperative Oncology Group 02 Expected life span 6 month . No distant metastasis Adequate bone marrow function ( absolute neutrophil count≥ 1,500/ul , blood platelet≥ 100,000/ul , haemoglobin≥ 10g/dl ) Adequate renal function ( serum creatinine ≤ 1.5mg/dl ) Adequate liver function ( serum bilirubin ≤ 1.5mg/dl , aspartate aminotransferase/alanine aminotransferase ≤ 3 time ( normal value ) Written inform consent Previous history chemotherapy radiation Hypersensitive reaction platinum/paclitaxel agent History cancer Concurrent systemic illness appropriate chemotherapy Active infection require antibiotic Pregnancy Metastasis paraaortic lymph node</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>postoperative therapy</keyword>
	<keyword>chemotherapy</keyword>
</DOC>